Tributyrin — Research Profile

Tributyrin is a triglyceride that protects butyrate from stomach acid and releases it in the intestines and colon where it is actually needed. Sodium butyrate releases butyrate immediately in the stomach, where most of it is absorbed before reaching the colon. Tributyrin also avoids the notoriously unpleasant rancid smell and taste associated with sodium butyrate supplements. For targeted colon delivery, tributyrin is the superior form.

Your gut bacteria naturally produce butyrate when they ferment dietary fiber. Eating 25-35g of fiber daily from diverse sources (beans, oats, bananas, garlic, onions) supports endogenous butyrate production. However, many people consume only 15g of fiber daily, and factors like antibiotic use, stress, and low-fiber diets can reduce butyrate-producing bacteria. Supplemental tributyrin can help bridge the gap while you work on improving fiber intake.

Many people notice improvements in bloating and bowel regularity within 1-2 weeks. However, meaningful gut barrier repair and microbiome modulation typically require 4-8 weeks of consistent daily use. For post-antibiotic recovery, a minimum 4-week course is generally recommended.

Tributyrin is itself a delivery form: a triglyceride prodrug that carries three butyrate molecules and releases them via lipase in the gut, which is why it is chosen over plain sodium butyrate. A depression-trial protocol selected tributyrin for its greater encapsulation efficiency, fitting 500 mg of tributyrin into a softgel versus 150 mg of sodium butyrate per capsule, so fewer capsules are needed to reach the target dose and adherence improves. No head-to-head human trial has compared tributyrin softgels against sodium butyrate for actual health outcomes.

Oral tributyrin has no proven clinical benefit in humans. Most support is mechanistic: butyrate acts as a histone deacetylase inhibitor and G-protein-coupled-receptor signal, strengthens the intestinal barrier, and has anti-inflammatory effects, but these come from reviews of endogenous butyrate, and its role in outcomes like obesity is described as controversial. The strongest tributyrin-specific data are in livestock (growth and litter outcomes in pigs and sows), while small human pilots raise butyrate exposure without confirming a clinical endpoint.

No clinically validated dose has been established. Human studies span a wide range: 100-200 mg/day in a healthy-adult pilot, up to 2 g of a butyrate-based triglyceride as a single dose, and a planned 4 g/day in a depression trial. Commercial products commonly supply 300-1000 mg taken with meals, but because no dose has demonstrated a defined clinical benefit, any amount is best regarded as exploratory.

Timing has not been directly compared in trials. Because pancreatic lipase released during digestion cleaves tributyrin into absorbable butyrate, taking it with food, particularly a meal containing some fat, is the practical choice, and the human pharmacokinetic study administered it within a fat-containing meal. There is no evidence that morning versus evening dosing changes results.

The most commonly reported side effects are mild digestive symptoms, mainly bloating, gas, and diarrhea, seen in fewer than 10% of healthy adults in a short-term pilot. Butyrate also has a strong rancid odor and taste that can cause unpleasant burping or reflux. Serious adverse events were not reported in the brief human studies conducted so far, though the total human safety experience is small.

No human drug-interaction studies have been conducted on tributyrin, so no interactions are documented. Butyrate does act pharmacologically as a histone deacetylase inhibitor, a mechanism shared with some prescription drugs, but whether food-supplement doses reach levels that affect medications is unknown. This is an absence of evidence rather than evidence of safety, so anyone on prescription therapy should treat interaction risk as uncharacterized.

No population has a demonstrated benefit from oral tributyrin, so it should be viewed as experimental rather than indicated for anyone. Interest centers on gut-barrier and intestinal health, reflecting butyrate's role as the main fuel for colon cells, but the human evidence for supplementing tributyrin is preliminary. People who are pregnant or breastfeeding, taking medication, or managing a gastrointestinal disease have no safety data to rely on and are the least appropriate candidates.

There is no reliable human timeline for clinical results from tributyrin. It is cleaved to butyrate within hours of a meal, and a single-dose crossover study in men with overweight/obesity raised circulating butyrate the same day, but that is a pharmacokinetic marker rather than a health benefit. The one placebo-controlled pilot in healthy adults ran 21 days of active supplementation and found only marginal biomarker shifts, so any symptomatic effect and its onset remain uncharacterized.

Long-term safety of oral tributyrin has not been established. The longest completed controlled human exposure is roughly three weeks, where it was well-tolerated in healthy adults, and the only multi-week protocol (8 weeks at 4 g/day as an antidepressant add-on) is a published trial design with no results yet reported. No human data extend beyond about two months, so daily use over longer periods is unstudied.

No tolerable upper limit exists for tributyrin because it is not an essential nutrient and has no RDA or UL. The dose-related effect reported in humans is mild gastrointestinal upset (bloating, gas, diarrhea) in a minority of users at 100-200 mg/day. Larger intakes have been tolerated short-term, including up to 2 g of a butyrate/hexanoate triglyceride in a single meal and a planned 4 g/day, but no toxicity threshold has been defined.

No human studies have tested tributyrin alongside other supplements, so there is no evidence any pairing improves outcomes. Conceptually it overlaps with dietary fiber and prebiotics, since the gut normally produces butyrate by fermenting non-absorbed carbohydrates, but taking a butyrate prodrug on top of fiber has not been shown to add benefit. Absence of interaction data means combinations are unproven rather than confirmed safe.

Check the label for the actual tributyrin dose in milligrams, since products vary widely and some list only a proprietary blend. Tributyrin is the glyceride (triglyceride) form of butyrate, distinct from sodium butyrate, and is sold as capsules or softgels sometimes under branded complexes such as ButyraGen. There is no potency or purity standardization marker for this ingredient, so third-party testing for identity and contaminants is the main quality signal.